Wall Street Zen upgraded shares of Retension Pharmaceuticals (NASDAQ:RTSN – Free Report) to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.
RTSN has been the subject of several other research reports. Zacks Research initiated coverage on shares of Retension Pharmaceuticals in a report on Wednesday, November 4th. They set a “hold” rating for the company. Leerink Partners began coverage on shares of Retension Pharmaceuticals in a report on Tuesday, November 3rd. They issued a “strong-buy” rating on the stock. Oppenheimer began coverage on shares of Retension Pharmaceuticals in a report on Tuesday, November 3rd. They issued an “outperform” rating and a $50.00 price objective on the stock. Finally, Guggenheim assumed coverage on shares of Retension Pharmaceuticals in a research report on Monday, November 2nd. They set a “buy” rating and a $55.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $52.50.
Check Out Our Latest Stock Report on RTSN
Retension Pharmaceuticals Stock Up 0.2%
Insider Buying and Selling at Retension Pharmaceuticals
In other Retension Pharmaceuticals news, Director Franklin Berger purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $120,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric Keller acquired 20,800 shares of the stock in a transaction on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $249,600.00. Following the completion of the transaction, the chief executive officer directly owned 423,377 shares in the company, valued at $5,080,524. The trade was a 5.17% increase in their position. The SEC filing for this purchase provides additional information.
About Retension Pharmaceuticals
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
Recommended Stories
- Five stocks we like better than Retension Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
